Nektar Therapeutics names Linda Rubinstein interim CFO
Updated
Updated · MarketWatch · May 8
Nektar Therapeutics names Linda Rubinstein interim CFO
7 articles · Updated · MarketWatch · May 8
The appointment takes effect on 15 May, replacing retiring interim finance chief Sandra Gardiner, who has held the role since 2023.
Rubinstein, a partner at FLG Partners, has served as permanent and interim CFO at several public and private biotech companies, including Adverum Biotechnologies and Five Prime.
Nektar said Gardiner will support the transition as needed and amended its FLG consulting agreement to pay $650 an hour for Rubinstein's services.
Can a new $650/hour CFO steer Nektar through class-action lawsuits and restore investor faith?
With $1B in cash but facing legal turmoil, is Nektar's new CFO a sign of strength or instability?